News Sentiment

ANTX sentiment intelligence

AN2 Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.50 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+1.8% over one week, -5.1% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Price to book forward of AN2 Therapeutics, Inc. – NASDAQ:ANTX

Market Reaction

Balanced read

65/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction 1.8% Price digesting
Trend fit Trend active -5.1% over four weeks
Fair value -1.5% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 32
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
TradingView 7
Market source 5
dars.gov.et 3
Business Wire 3
simplywall.st 3
Investing.com 2
www.marketscreener.com 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 16
Balance sheet 4
Analyst action 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
TradingView Direct company coverage

Price to book forward of AN2 Therapeutics, Inc. – NASDAQ:ANTX

This article provides access to the "Price to book forward" financial metric for AN2 Therapeutics, Inc. (NASDAQ: ANTX) on the TradingView platform. It highlights that the market is closed and no trades have occurred for this specific metric, with data provided by ICE Data Service

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 14:40
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 AN2 Therapeutics Inc For: 10 July By Investing.com

This article provides details about a Form 4 filing for AN2 Therapeutics Inc. on July 10, 2026. It mentions the company's stock symbol ANTX and includes a Reuters image. The filing date is explicitly stated as July 10, 2026.

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 12:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

AN2 Therapeutics (ANTX) officer sale covers RSU tax withholding, retains 206,554 shares

AN2 Therapeutics officer Joshua M. Eizen sold 5,945 shares of common stock at $4.172 per share on July 8, 2026. This sale was explicitly for tax withholding obligations from Restricted Stock Unit vesting and not a discretionary transaction. After this sale, Eizen still holds 206,

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 12:10
Source
Stock Titan
Stock Titan Direct company coverage

AN2 Therapeutics (ANTX) director granted 766 shares in lieu of cash fees

AN2 Therapeutics (ANTX) director Patricia A. Martin received a grant of 766 shares of common stock on July 10, 2026. These shares were awarded in lieu of cash fees as per the company's non-employee director compensation policy and vested immediately. This transaction increases he

Tone
Neutral 50/100
Event
Balance sheet
Published
11 Jul 2026 00:09
Source
Stock Titan
Stock Titan Direct company coverage

AN2 Therapeutics (ANTX) director receives 2,789-share stock grant in lieu of cash

AN2 Therapeutics director Gilbert Lynn Marks received a grant of 2,789 shares of common stock on July 10, 2026, as compensation instead of cash, with the shares vesting immediately. This transaction, made under the company's non-employee director compensation policy, increases Ma

Tone
Neutral 50/100
Event
Balance sheet
Published
11 Jul 2026 00:09
Source
Stock Titan
Stock Titan Direct company coverage

AN2 Therapeutics (ANTX) director Aziz Kabeer granted 2,852 shares as fees

Aziz Kabeer, a director at AN2 Therapeutics (ANTX), received a grant of 2,852 shares of common stock on July 10, 2026, as compensation for his non-employee director services, issued in lieu of cash. These shares vested immediately, and following this transaction, Kabeer directly

Tone
Neutral 50/100
Event
Balance sheet
Published
11 Jul 2026 00:09
Source
Stock Titan
Investing.com Direct company coverage

An2 therapeutics COO Joshua Eizen sells $24,802 in stock

Joshua M. Eizen, COO and Chief Legal Officer at AN2 Therapeutics, Inc. (NASDAQ:ANTX), sold 5,945 shares of company stock for $24,802 to cover tax withholding obligations from vested RSUs. Following the sale, Eizen still holds 206,554 shares, including various tranches of RSUs and

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 23:09
Source
Investing.com
Investing.com Canada Direct company coverage

An2 therapeutics COO Joshua Eizen sells $24,802 in stock By Investing.com

Joshua M. Eizen, COO and Chief Legal Officer at AN2 Therapeutics (NASDAQ:ANTX), sold 5,945 shares of company stock worth $24,802 to cover tax obligations from RSU vesting. Following the sale, Eizen still holds 206,554 shares. AN2 Therapeutics, while not yet profitable, has a stro

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 22:10
Source
Investing.com Canada
www.marketscreener.com Direct company coverage

AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to Russell 3000E Growth Benchmark

AN2 Therapeutics, Inc. (NasdaqGS: ANTX) has been added to the Russell 3000E Growth Benchmark. This addition, effective June 29, 2026, reflects the company's growth in the biotechnology and medical research sector. The article also highlights multiple other Russell index inclusion

Tone
Positive 74/100
Event
Market update
Published
29 Jun 2026 23:09
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

AN2 Therapeutics, Inc.(NasdaqGS: ANTX) added to Russell 2000 Value Benchmark

AN2 Therapeutics, Inc. (NasdaqGS: ANTX) has been added to the Russell 2000 Value Benchmark. The company is a biopharmaceutical firm focused on developing novel small molecule therapeutics using its boron chemistry platform, with its lead candidate, epetraborole, targeting non-tub

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 16:09
Source
www.marketscreener.com
TradingView Direct company coverage

ANTX Forecast — Price Target — Prediction for 2027

This article provides an in-depth forecast for AN2 Therapeutics, Inc. (ANTX) stock, including analyst price targets and historical performance data. It also addresses frequently asked questions regarding ANTX's current price, volatility, market capitalization, earnings reports, a

Tone
Positive 70/100
Event
Analyst action
Published
28 Jun 2026 17:41
Source
TradingView
TradingView Direct company coverage

AN2 Therapeutics, Inc. Actuals & Estimates (NASDAQ:ANTX)

AN2 Therapeutics, Inc. (NASDAQ: ANTX) stock has seen significant growth, with a 377.06% increase over the last year. Analysts have a consistent price target of $9.00 USD. The company's market capitalization stands at $185.12 million, and its next earnings report is expected on Au

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of AN2 Therapeutics, Inc. – NASDAQ:ANTX

This article provides the "Price to earnings forward" value for AN2 Therapeutics, Inc. (NASDAQ: ANTX) within the context of TradingView's financial data. It indicates the stock's market status and references the data sources used. The specific financial value is not detailed, but

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:11
Source
TradingView
TradingKey Direct company coverage

AN2 Therapeutics Inc (ANTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for AN2 Therapeutics Inc (ANTX), highlighting an analyst rating of "Strong Buy" based on one analyst's assessment. It includes the current stock price, market cap, and projected target price, along with recent and expected EPS figures. T

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:09
Source
TradingKey
TradingKey Direct company coverage

AN2 Therapeutics Inc (ANTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for AN2 Therapeutics Inc (ANTX) but states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. It provides current stock informat

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 05:39
Source
TradingKey
TradingView Direct company coverage

Number of shareholders of AN2 Therapeutics, Inc. – NASDAQ:ANTX

This article provides details on the number of shareholders for AN2 Therapeutics, Inc. (NASDAQ: ANTX). It presents a table with "Period," "Value," and "Change %" columns, though the data itself is not displayed in the provided content. The information is sourced from ICE Data Ser

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 17:09
Source
TradingView
The Globe and Mail Direct company coverage

AN2 Therapeutics Holds 2026 Annual Stockholder Meeting

AN2 Therapeutics, Inc. held its 2026 annual meeting on June 3, 2026, where stockholders elected three Class I directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm. Despite concerns about weak financial performance, the company's s

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 14:10
Source
The Globe and Mail
Stock Titan Direct company coverage

Shareholders back AN2 Therapeutics (NASDAQ: ANTX) directors and auditor

AN2 Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders, where a quorum of 63.18% of outstanding shares was present. Shareholders elected Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D., as Class I directors until the 2029 annual meet

Tone
Neutral 50/100
Event
Earnings
Published
09 Jun 2026 22:10
Source
Stock Titan
Investing.com Direct company coverage

AN2 Therapeutics reports positive Chagas disease trial results

AN2 Therapeutics Inc. announced positive results from two studies for AN2-502998, an oral treatment for chronic Chagas disease. The drug achieved complete parasite elimination in nonhuman primates and was well-tolerated in a Phase 1 human study, boosting ANTX shares. The company

Tone
Positive 71/100
Event
Earnings
Published
04 Jun 2026 22:09
Source
Investing.com
Stock Titan Direct company coverage

AN2 Therapeutics (Nasdaq: ANTX) posts strong early Chagas trial data

AN2 Therapeutics announced positive early-stage data for its oral CPSF3 inhibitor AN2-502998 for chronic Chagas disease. A 28-day nonhuman primate study showed 100% parasite elimination, and a Phase 1 human trial demonstrated a favorable safety and tolerability profile. The compa

Tone
Positive 87/100
Event
Market update
Published
04 Jun 2026 20:15
Source
Stock Titan
Business Wire Direct company coverage

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

AN2 Therapeutics announced positive results for its oral drug AN2-502998, intended for chronic Chagas disease. Studies in nonhuman primates showed 100% parasitic elimination after 28 days of treatment, and a Phase 1 human study demonstrated a favorable safety profile. These findi

Tone
Positive 93/100
Event
Earnings
Published
04 Jun 2026 11:10
Source
Business Wire
Stock Titan Direct company coverage

AN2 Therapeutics (ANTX) officer sells 265 shares to cover RSU taxes

AN2 Therapeutics Principal Accounting Officer Sarah Joanne Williams sold 265 shares of common stock at $4.43 per share. This transaction was not a discretionary sale but rather a routine tax-related event to satisfy withholding obligations from vested Restricted Stock Units (RSUs

Tone
Neutral 50/100
Event
Market update
Published
02 Jun 2026 20:19
Source
Stock Titan